


**Please cite the Published Version**

Hawley, John , Forster, Samuel C. and Giles, Edward M. (2025) Exercise, Gut Microbiome, and Gastrointestinal Diseases: Therapeutic Impact and Molecular Mechanisms. *Gastroenterology*. ISSN 0016-5085

**DOI:** <https://doi.org/10.1053/j.gastro.2025.01.224>

**Publisher:** Elsevier

**Version:** Accepted Version

**Downloaded from:** <https://e-space.mmu.ac.uk/638497/>

**Usage rights:**  [Creative Commons: Attribution 4.0](https://creativecommons.org/licenses/by/4.0/)

**Additional Information:** This is an open access article published in *Gastroenterology*, by Elsevier.

**Enquiries:**

If you have questions about this document, contact [openresearch@mmu.ac.uk](mailto:openresearch@mmu.ac.uk). Please include the URL of the record in e-space. If you believe that your, or a third party's rights have been compromised through this document please see our Take Down policy (available from <https://www.mmu.ac.uk/library/using-the-library/policies-and-guidelines>)

# Exercise, Gut Microbiome, and Gastrointestinal Diseases: Therapeutic Impact and Molecular Mechanisms

John A. Hawley,<sup>1,2</sup> Samuel C. Forster,<sup>3,4</sup> and Edward M. Giles<sup>3,5</sup>

<sup>1</sup>The Mary MacKillop Institute for Health Research, Australian Catholic University, Melbourne, Victoria, Australia; <sup>2</sup>Department of Sport and Exercise Sciences, Manchester Metropolitan University Institute of Sport, Manchester, United Kingdom; <sup>3</sup>Centre for Innate Immunity and Infectious Diseases, Hudson Institute of Medical Research, Clayton, Victoria, Australia; <sup>4</sup>Department of Molecular and Translational Sciences, Monash University, Clayton, Victoria, Australia; and <sup>5</sup>Department of Paediatrics, Monash University, Clayton, Victoria, Australia

The benefits of regular physical activity (PA) on disease prevention and treatment outcomes have been recognized for centuries. However, only recently has interorgan communication triggered by the release of “myokines” from contracting skeletal muscles emerged as a putative mechanism by which exercise confers protection against numerous disease states. Cross-talk between active skeletal muscles and the gut microbiota reveal how regular PA boosts host immunity, facilitates a more diverse gut microbiome and functional metabolome, and plays a positive role in energy homeostasis and metabolic regulation. In contrast, and despite the large interindividual variation in the human gut microbiome, reduced microbial diversity has been implicated in several diseases of the gastrointestinal (GI) tract, systemic immune diseases, and cancers. Although prolonged, intense, weight-bearing exercise conducted in extreme conditions can increase intestinal permeability, compromising gut-barrier function and resulting in both upper and lower GI symptoms, these are transient and benign. Accordingly, the gut microbiome has become an attractive target for modulating many of the positive effects of regular PA on GI health and disease, although the precise dose of exercise required to induce favourable changes in the microbiome and enhance host immunity is currently unknown. Future efforts should concentrate on gaining a deeper understanding of the factors involved in exercise-gut interactions through the generation of functional ‘omics readouts (ie, metatranscriptomics, metaproteomics, and metabolomics) that have the potential to identify functional traits of the microbiome that are linked to host health and disease states, and validating these interactions in experimental and preclinical systems. A greater understanding of how PA interacts with the GI tract and the microbiome may enable targeted therapeutic strategies to be developed for individuals and populations at risk for a variety of GI diseases.

**Keywords:** AMPK; Cross-Talk; Fecal Microbiota Transfer; Gastrointestinal Tract; Immunity; Inflammation; Ischemia; mTOR; Myokines; Physical Activity; Probiotics; Skeletal Muscle.

Epidemiologic and cross-sectional data provide overwhelming evidence to demonstrate that lifelong physical activity (PA, defined as voluntary bodily movement produced by skeletal muscles that requires energy expenditure) postpones the onset of numerous chronic metabolic

conditions and noncommunicable diseases (NCDs) and is associated with an enhanced quality of life and extended health span.<sup>1–6</sup> In this regard, there has been belated recognition that “exercise is medicine” with the advancement and implementation of evidence-based approaches to elevate the status of PA in primary healthcare settings.<sup>7–11</sup> Many interdependent mechanisms underpin the health-promoting effects of PA although the precise molecular bases by which lifelong PA (ie, exercise training) promotes human health and reduces disease risk remain poorly understood.<sup>12</sup> Although the biochemical and metabolic adaptations to exercise training have been extensively investigated in skeletal muscle, heart, adipose tissue, and the vasculature,<sup>13</sup> only recently has there been appreciation that the gut microbiome plays a fundamental role in promoting some of the beneficial effects of regular PA on both general health, athletic performance, and anticancer immunity.<sup>14–16</sup> Murine models using a variety of exercise interventions reveal consistent changes in the gut microbiome associated with improved health outcomes and longevity.<sup>17</sup> Despite less than 5% overlap between human and mouse microbiota composition<sup>18</sup> and several interspecies differences,<sup>19</sup> such investigations provide opportunities for examining the mechanistic interactions between exercise and the gut microbiota that may be of direct translational value for discovering the functional processes underlying several human gastrointestinal (GI) disease states.<sup>20,21</sup>

The gut microbiome constantly interacts with the host immune system, producing a range of metabolites that exert both local (cell/tissue/organ) and systemic (whole-body) effects.<sup>22</sup> These interactions can trigger health or disease states by generating either harmful metabolites that

**Abbreviations used in this paper:** AMPK, AMP-activated protein kinase; BMI, body mass index; CI, confidence interval; CRC, colorectal cancer; FMT, fecal microbiota transplantation; GI, gastrointestinal; IBD, inflammatory bowel disease; IBS, irritable bowel syndrome; IL, interleukin; MASLD, metabolic dysfunction-associated steatotic liver disease; MET, metabolic equivalent; mTOR, Akt/mammalian target of rapamycin; NK, natural killer; NCD, noncommunicable disease; PA, physical activity; RR, relative risk; SCFA, short-chain fatty acids; TNF- $\alpha$ , tumor necrosis factor alpha; VO<sub>2</sub>max, maximal oxygen consumption.

© 2025 The Author(s). Published by Elsevier Inc. on behalf of the AGA Institute. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).

0016-5085

<https://doi.org/10.1053/j.gastro.2025.01.224>

121 provoke disorders (eg, inflammatory bowel disease [IBD])  
 122 or favorable metabolites (ie, short-chain fatty acids [SCFA])  
 123 that are health-promoting. For this reason, the role of the  
 124 gut microbiome on its host has been the focus of intense  
 125 research, with the gut microbiota now established as a  
 126 powerful modulator of the efficacy of several treatments of  
 127 GI diseases. There has been an emergence of clinical in-  
 128 terventions targeting the microbiome to enhance health  
 129 outcomes, particularly cancer,<sup>23</sup> from diagnosis and recur-  
 130 rence to prognosis as well as treatment effectiveness.<sup>24</sup> Here  
 131 we discuss the role of PA and skeletal muscle metabolic  
 132 cross-talk with other tissues and organs, especially the GI  
 133 tract, with a focus on how exercise can modulate microbial  
 134 diversity. We describe the effects of exercise on the GI tract  
 135 concentrating on the role of bacteria and other micro-  
 136 organisms in this process. Finally, the role of exercise and  
 137 the gut microbiome in the prevention of GI diseases will be  
 138 discussed in anticipation of emerging treatments that target  
 139 the microbiome to modulate these effects by understanding  
 140 the complex and interdependent interactions between PA,  
 141 diet, and GI function.

## 142 Metabolic Communication During 143 Exercise

### 144 Skeletal Muscle Cross-Talk


145 The health-promoting effects of regular PA have tradi-  
 146 tionally been attributed to exercise-induced increases in  
 147 whole-body cardiorespiratory fitness ( $VO_{2max}$ ) evoked by  
 148 extensive remodelling of the vascular system, especially the  
 149 peripheral skeletal muscles subjected to exercise.<sup>13</sup> How-  
 150 ever, during the past 20 years, interorgan communication or  
 151 “cross-talk” initiated by contracting skeletal muscles has  
 152 emerged as a complementary mechanism through which PA  
 153 confers protection against an array of disease states.<sup>25</sup>  
 154 Although the hypothesis of a “general, humoral effect of  
 155 exercise” was proposed more than 60 years ago,<sup>26</sup> the  
 156 concept of skeletal muscle as an endocrine organ gained  
 157 credibility just 2 decades ago when it was shown that the  
 158 cytokine interleukin-6 (IL6) was released from skeletal  
 159 muscle during exercise.<sup>27</sup> Since that time, cytokines and  
 160 other peptides, which are released by contracting skeletal  
 161 muscle fibers and exert autocrine, paracrine, or endocrine  
 162 effects, have been classified as “myokines.”<sup>28,29</sup> The list of  
 163 bona fide myokines includes IL6, IL8, IL15, decorin,  
 164 follistatin-like 1, fibroblast growth factor-21, irisin, chemo-  
 165 kine CXC motif ligand-1 also known as keratinocyte-derived  
 166 chemokine, mitochondrially encoded peptide-c and  
 167 meteorin-like, although there are likely many more proteins  
 168 secreted by contracting skeletal muscles.<sup>25,29</sup> Established  
 169 roles for “adipokines” and “hepatokines” as exercise-  
 170 stimulated signals that coordinate systemic metabolism in  
 171 response to PA and inactivity have been reviewed previ-  
 172 ously.<sup>25,30,31</sup> The discovery of interorgan cross-talk offers a  
 173 framework for understanding how PA transmits many of its  
 174 beneficial effects on whole-body metabolic health (Figure 1).

175 Recently, important links between skeletal muscle and  
 176 the gut microbiota have been uncovered, revealing how

181 exercise facilitates a more diverse gut microbiome and  
 182 functional metabolome, casting new light on the inter-  
 183 connectivity between these 2 organs in health and disease  
 184 states.<sup>32</sup> Exercise training alters both the bacterial commu-  
 185 nity structure and numerous taxa that are associated with  
 186 improved host health.<sup>33</sup> However, these exercise-induced  
 187 changes are not universal with only moderate to high-  
 188 intensity exercise undertaken more than 3 times per week  
 189 for longer than 8 weeks being consistently associated with  
 190 either alterations in bacterial community and/or community  
 191 structure.<sup>34</sup> In that analysis, the health status of the cohort  
 192 under investigation created variability and potential con-  
 193 founders in results,<sup>34</sup> with a rather liberal definition of  
 194 “healthy” that included individuals with no defined exclu-  
 195 sion criteria in terms of chronic illness.

196 Contemporary investigations show that the gut microbiota  
 197 exerts multiple effects on skeletal muscle bioenergetics<sup>35</sup> and  
 198 have revealed how the gut bacteria respond to an exercise  
 199 challenge with reciprocal roles in fuel availability, muscle  
 200 function, and endurance capacity.<sup>16,36</sup> The notion of cross-talk  
 201 between the gut microbiota and contracting skeletal muscle  
 202 emerged from studies in rodents showing increases in several  
 203 species of SCFAs (acetate, butyrate, propionate, and conju-  
 204 gated linoleic acid) after endurance training.<sup>37-39</sup> Although  
 205 early studies demonstrated that SCFAs were absorbed in both  
 206 the small and large intestine by similar mechanisms, it is now  
 207 accepted that there exist species differences in SCFA pro-  
 208 ducers as well as different transporter isoforms expressed in  
 209 enterocytes along the intestine.<sup>40</sup> SCFAs have a protective  
 210 effect on the host by reducing inflammation through tran-  
 211 scriptional inhibition of cytokines and inflammatory proteins.  
 212 Among the SCFAs, butyrate has received considerable atten-  
 213 tion for its beneficial effects on both cellular energy meta-  
 214 bolism and intestinal homeostasis: butyrate is the primary  
 215 fuel for colonocytes, increasing colonic epithelial cell prolifer-  
 216 ation, promoting gut barrier integrity, and regulating host  
 217 gene expression and immunity.<sup>41</sup>

218 Compelling evidence for the existence of a “muscle-gut  
 219 axis” came from the study of Lahiri et al<sup>42</sup> who compared  
 220 the skeletal muscle of germ-free mice that lacked a gut  
 221 microbiota to the skeletal muscle of pathogen-free mice with  
 222 an intact functional gut microbiota. In contrast to pathogen-  
 223 free mice, skeletal muscle from the germ-free animals dis-  
 224 played significant atrophy and reduced muscle strength,  
 225 underpinned by a decreased expression of insulin-like  
 226 growth factor-1 along with reduced transcription of genes  
 227 associated with skeletal muscle growth and mitochondrial  
 228 function. Treating germ-free mice with a cocktail of SCFAs  
 229 resulted in a reduced expression of *Atrogin-1* and an  
 230 increased expression of myoblast determination protein-1,  
 231 and partially reversed the functional impairments to mus-  
 232 cle. These data support a role for the gut microbiota in  
 233 regulating skeletal muscle mass and function, although  
 234 whether this is a direct effect or immune-mediated remains  
 235 to be determined. The influence of the microbiota-derived  
 236 SCFA on hosts includes proliferation, differentiation, and  
 237 aspects of metabolism, with most of these functions acting  
 238 via gene expression, with butyrate modulating the expres-  
 239 sion of >20% of genes in humans.<sup>43</sup>



**Figure 1.** Skeletal muscle cross-talk. Regular PA has both acute and chronic effects on multiple organ systems. In response to contractile stimuli, skeletal muscles secrete a range of molecules that “communicate” with other tissues and organs including adipose tissue, liver, brain, gut, bone, and the GI tract. While the majority of myokines are released from skeletal muscle in response to an acute bout of exercise, adipokines and hepatokines exert their biological function in response to repeated exercise stimuli through changes in whole-body metabolism. The release of cytokines and other mediators, alongside neurologic and vascular changes induced by exercise, modulate the intestinal barrier and gut function. Such changes are highly individual and are modified by the prevailing exercise challenge (mode, intensity, duration, and environmental conditions), an individual’s habitual diet, and the microbiome. Exercise training is associated with increased microbial diversity and abundance of bacterial species, increasing SCFAs, whereas reduced microbial diversity in human intestines has been implicated in several GI diseases and CRC, with the microbiome exacerbating inflammation or other disease processes with immunomodulatory functions. BAIBA,  $\beta$ -aminoisobutyric acid; BDNF, brain-derived neurotrophic factor; FFA, free fatty acids; FGF-2, fibroblast growth factor-2; IGF-1, insulin-like growth factor 1; LPS, lipopolysaccharides; Metrn, meteorin-like; SPARC, secreted protein acidic rich in cysteine. Created in BioRender. Belhaj M. (2025) <https://BioRender.com/s64m052>.

The first evidence demonstrating that exercise training in humans was associated with increased microbial diversity and abundance of bacterial species came from cross-sectional studies on well-trained athletic populations. Clarke et al<sup>44</sup> reported that professional rugby players had higher alpha diversity and a greater relative abundance of the health-associated genus *Akkermansia* compared with high-

and low-body mass index (BMI) sedentary controls. Subsequent observational studies revealed that trained states were associated with a higher alpha diversity, an enrichment of beneficial taxa, and a higher abundance of fecal SCFAs.<sup>16</sup> In these investigations,  $VO_{2max}$  accounted for up to a quarter of the variation in taxonomic richness after allowing for all other factors including diet,<sup>45</sup> with higher



levels of fitness associated with a greater degree of both alpha and beta diversity.<sup>44–47</sup> These observations suggest that a high level of cardiorespiratory fitness is related to certain bacterial species and metabolite production, which have been implicated in several disease states including reduced cancer risk.<sup>23</sup> Indeed, a recent study reported greater gut microbiome diversity and differential abundances between colorectal cancer (CRC) survivors who were physical active compared with those who were inactive,<sup>48</sup> with active patients having enriched abundance of multiple dominant genera including *Faecalibacterium* and *Blautia* and less dominant genera including *Succinivibrio* and *Succinivibrio*. At the phylum level, active patients had lower Actinobacteria abundance. These findings are consistent with studies showing higher abundances of *Succinivibrio*, *Faecalibacterium prausnitzii*, *Roseburia hominis*, and *Akkermansia muciniphila* in healthy individuals and athletes.<sup>44,45,47</sup> *Faecalibacterium* and *Succinivibrio* have been linked to health-promoting attributes including decreased risk for CRC.<sup>49</sup>

Further evidence of a muscle-gut axis comes from the work of Scheiman et al.<sup>50</sup> Using 16S rRNA profiling, these workers reported a higher abundance of *Veillonella* in 15 runners who completed the 2015 Boston marathon compared with a group of 10 healthy but sedentary controls. *Veillonella* species metabolize lactate into the SCFAs acetate and propionate via the methylmalonyl-CoA pathway and, although many other microbes have the capacity to use lactate, they do not possess the full pathway to convert lactate to propionate. Using intracolonic infusion, a strain of *Veillonella atypica* was isolated from stool samples of the runners and when this strain was inoculated into mice, treadmill running time to exhaustion was significantly increased. These findings are intriguing as they highlight that the microbiome may be a critical component of endurance performance but raise the question of how this performance-facilitating organism came to be more prevalent among endurance-trained athletes in the first place.

In contrast, reduced microbial diversity has been implicated in many GI diseases<sup>51,52</sup> although direct causation remains to be determined. In severe liver disease and IBD, antibiotics are frequently prescribed, leading to periods of significantly reduced microbial diversity, potentially driving ongoing disease pathogenesis. Such microbial effects are also strongly associated with sarcopenia, defined as a loss of skeletal muscle mass, which is often seen in parallel with these diseases and is closely related to levels of PA.<sup>53,54</sup> This “dysbiosis” affects host metabolism and the functionality and pathophysiology of several peripheral organs with exercise a potential intervention to perturb gut microbiota composition and re-establish gut symbiosis. There is a large variation in the outcomes of exercise on the microbiome across studies<sup>38,55,56</sup> due to the complexity of the interaction with individual microbiome variation, different participant cohorts, the exercise dose (ie, the intensity, duration, and frequency) and other variables (diet, cultural, and geographical demographics).<sup>57</sup> For example, the relative abundance of *Prevotella* is associated with endurance-based exercise programs,<sup>58</sup> whereas in athletes who undertake


more intense power-based training, there is marked intestinal inflammation and greater abundance of bacteria involved in inflammatory processes such as *Haemophilus*, *Rothia*, *Mucispirillum*, and *Ruminococcus gnavus*.<sup>59,60</sup> Although the optimal dose of exercise to induce favourable changes in the gut microbiota is unknown, it is likely to be specific to an individual’s prevailing health status and background diet. Results from a recent investigation demonstrate that exercise training-induced alterations to gut microbiota composition and function were dependent on the body composition of participants. Allen et al<sup>61</sup> reported that short-term endurance exercise training increased fecal concentrations of SCFAs in lean individuals (BMI <25 kg/m<sup>2</sup>) but not those with obesity (BMI >30 kg/m<sup>2</sup>), an observation that was independent of diet. Of note, the exercise-induced changes to the microbiota, VO<sub>2max</sub>, and body composition were rapidly lost in both cohorts when the training stimulus was terminated, suggesting that shifts in the metabolic capacity of the gut microbiota were strongly associated with the prevailing fitness levels, were transient, and were highly dependent on a regular exercise stimulus. Clearly, regular PA is necessary to produce favorable long-term modifications in the gut microbiota composition, largely through immune-metabolic pathways associated with anti-inflammatory effects.<sup>61–63</sup> Further studies are required to understand the mechanisms that regulate changes in the composition and functions of the microbiome caused by PA along with their related effects.<sup>33</sup>

## Diseases of the GI Tract and Effects of Exercise on GI Symptoms

Acute exercise has diverse effects on the GI tract (Figure 2) that can broadly be divided into upper (ie, heartburn, belching, regurgitation, and epigastric pain) or lower GI symptoms (ie, nausea, diarrhea, blood loss, flatulence, urgency, and abdominal pain). Exercise affects both motility and absorptive properties of the GI tract, with acute exercise slowing transit times in the upper GI tract due to increased sympathetic nervous activity.<sup>64</sup> There is also a reduced absorptive capacity during exercise,<sup>65,66</sup> with increased nutrient load to the caecum and colon driving symptoms in the lower GI tract.<sup>67</sup> The altered nutrient environment also interacts with the resident microbiome as a potential modifier of such symptoms. Upper GI symptoms are more common than lower GI symptoms with prolonged (>90 min) weight-bearing exercise (ie, running) associated with a greater number and severity of symptoms.<sup>68,69</sup> GI problems are especially common in athletes training for and competing in endurance events with 30%–50% of athletes reporting 1 or more GI symptoms.<sup>70</sup> However, most GI symptoms are mild, transient, and of no risk to long-term health.

### Ischemia and inflammation

Changes in splanchnic blood flow underpin many of the adverse clinical effects of exercise on GI function<sup>71,72</sup> during which splanchnic ischemia leads to gut barrier



print &amp; web 4C/FPO

**Figure 2.** Clinical symptoms associated with “excessive” exercise challenges along with the protective effects of exercise training on GI diseases. Acute bouts of exercise can induce both upper and lower GI symptoms (*left*) depending on the prevailing exercise and environmental factors (*middle, lower*). Exercise training is associated with favorable outcomes for a number of GI diseases (*right*). Created in BioRender. Belhaj M. (2025) <https://BioRender.com/s64m052>.

disorders.<sup>73–75</sup> Such exercise-induced ischemia leads to systemic endotoxemia and an associated inflammatory response.<sup>76–79</sup> Historically intestinal damage has been measured after exercise through fecal blood loss<sup>80</sup> and more recently with intestinal-fatty acid binding protein<sup>75,81</sup> and calprotectin.<sup>75</sup> In healthy individuals intestinal permeability is related to the prevailing exercise-intensity with intense exercise (>80% of  $VO_{2max}$ ) resulting in greater increases in small intestinal permeability compared with exercise undertaken at 40%–60% of  $VO_{2max}$ . However, increases in permeability do not always result in a higher prevalence of GI symptoms and increased intestinal permeability.<sup>82</sup> A study of endurance-trained athletes performing 1 hour of intense cycling at 80% of  $VO_{2max}$  reported little effect on barrier function or self-reported GI symptoms,<sup>83</sup> suggesting there is considerable variability in the effect of both the relative exercise intensity and mode on gut damage, with well-trained individuals experiencing fewer GI disturbances compared with exercise-naïve subjects. Indeed, the GI tract is highly adaptable: gastric emptying as well as stomach comfort can be “trained” and perceptions of fullness decreases in athletes practicing a variety of nutritional strategies before and during exercise.<sup>84,85</sup>

Endotoxemia is suggestive of barrier dysfunction or damage, with either bacteria or their products translocating across the epithelial lining of the GI tract. Evidence of such dysfunction during PA is confounded by the different modes and intensities of exercise, the fitness level of subjects studied, and the various measures of gut damage used in investigations. This, in part, explains the wide range of outcomes reported, although one should also consider that the resident microbiome is another variable in exercise-induced barrier stress. For example, a high protein diet (1.5 g/kg body mass), commonly consumed by athletes training for strength/power events, may contribute to dysbiosis (eg, increased *Escherichia coli* lipopolysaccharide) and amplify intestinal damage and symptoms. As exercise intensity and duration increases, there is considerable evidence for increases in indices of intestinal injury, permeability, and endotoxemia, together with impairment of gastric emptying, slowing of small intestinal transit, and malabsorption.<sup>86</sup> The addition of heat stress and running mode exacerbates markers of GI disturbance, with an exercise duration of ~2 hours at a moderate (60% of  $VO_{2max}$ ) intensity seemingly the “threshold” at which significant GI perturbations occur.<sup>86</sup>

## The Potential Role of the Gut Microbiome as a Mechanism to Reduce GI Symptoms During Exercise

A potential role for the microbiome in modulating the effects of PA is through dietary interventions. Carbohydrate ingestion immediately before or during exercise attenuates GI symptoms and markers of intestinal damage<sup>87-89</sup> and, while this effect may be independent of the microbiome, increased carbohydrate availability may temper the dysbiosis reported by many athletes.<sup>86,90</sup> Other diets, including a gluten-free diet, have been investigated in an attempt to reduce GI symptoms, but appear ineffective.<sup>91</sup> To support the splanchnic circulation and reduce intestinal damage during exercise, the nitric oxide precursors and amino acid supplements L-arginine and L-citrulline supplements have been investigated, although their efficacy is equivocal.<sup>92,93</sup> Although these dietary interventions are likely to have moderate effects on the microbiome, it remains speculative whether they would exert any effect on exercise capacity, or the mechanism of such an effect.

Direct attempts to modulate the microbiome to preserve permeability and attenuate other exercise-induced barrier damage have been largely ineffective, including combinations comprising 6 (*Bifidobacterium bifidum*, *Bifidobacterium lactis*, *Enterococcus faecium*, *Lactobacillus acidophilus*, *L. brevis*, and *Lactococcus lactis*) and 9 probiotic strains (*L. acidophilus*, *Lactobacillus rhamnosus*, *Lactobacillus plantarum*, *Lactobacillus fermentum*, *Lactobacillus casei*, *Bifidobacterium breve*, *B. lactis*, *B. bifidum*, and *Streptococcus thermophilus*).<sup>94,95</sup> In a recent double-blind placebo-controlled trial, probiotic supplementation (*L. acidophilus* and *Bifidobacterium longum*) administered for 5 weeks to amateur runners reduced GI symptoms and was associated with less dysbiosis.<sup>96</sup> In a double-blind, crossover study 16 runners were randomized to 4 weeks of daily supplementation with a probiotic cocktail containing *Pediococcus acidilactici* bacteria and *L. plantarum* or placebo. Treadmill running tests (90 minutes at 65%–70% of  $VO_{2max}$  or until fatigue/GI symptoms developed, undertaken in 27°C) were performed before and after supplementation. GI symptoms, gut permeability-associated parameters (intestinal-fatty acid binding protein, lipopolysaccharide-binding protein, zonulin, and cytokines), and intestinal microbial content were not altered by the probiotic supplementation.<sup>97</sup> *L. casei* supplementation for 7 days before 2 hours of running at 60% of  $VO_{2max}$  in extreme (34°C) heat did not alter resting circulatory endotoxin concentration or plasma cytokine profile compared with a placebo, although there was a trend for higher plasma endotoxin and tumor necrosis factor alpha (TNF- $\alpha$ ) concentrations after exercise in the probiotic-supplemented group,<sup>98</sup> suggesting that changes to the microbiome may influence barrier function during PA, although not always favorably. Although probiotic supplementation has traditionally focused on gut health, in recent years, the clinical applications of probiotics have broadened to allergic, metabolic, inflammatory, GI, and respiratory conditions. Probiotic supplementation could yield small beneficial effects in promoting health in trained individuals,

likely by reducing the risk of respiratory and GI illness during intensified periods of training and competition but precise compositions and dosage regimes remain to be determined. Such benefits would most likely be mediated by changes in gut microbiota and enhanced mucosal barrier integrity in the GI and respiratory tracts.<sup>99</sup>

## The Potential Role of Exercise-Microbiome Cross-Talk in GI Diseases

Exercise undertaken according to the American College of Sports Medicine guidelines<sup>100</sup> is associated with improved health outcomes in numerous NCDs, including many nonmalignant conditions of the GI tract and also several cancers. Perhaps the most obvious GI condition linked with regular PA is metabolic dysfunction-associated steatotic liver disease (MASLD), with exercise recommended as a primary treatment across many international guidelines.<sup>101</sup> Although MASLD is intimately related to lack of PA, obesity, and a poor diet, not all sedentary people with obesity develop fatty infiltration of the liver. The gut microbiome is related to this complex interplay with a “gut-liver axis” of diet, genetics, and inflammation being potential drivers of the fibrosis and risk of hepatocellular carcinoma. Treatment strategies for these conditions should consider combining regular exercise with microbiome modulation to impact MASLD<sup>102</sup> because exercise can reverse gut “dysbiosis” in MASLD patients.<sup>103</sup>

IBD has 2 major phenotypic forms: Crohn’s disease and ulcerative colitis, with rising worldwide incidence. Although the precise etiology of IBD is unknown, several factors arising from adipose tissue and skeletal muscle have been implicated including cytokines, adipokines, and myokines.<sup>104</sup> In a high-fat-fed murine model of colitis, moderate-intensity exercise (voluntary wheel running) significantly decreased macroscopic and microscopic colitis, increased colonic blood flow, and attenuated plasma TNF- $\alpha$ , IL6, monocyte chemoattractant protein-1, IL1 $\beta$ , and leptin levels. In contrast, in sedentary mice fed the same diet, colonic lesions were aggravated, colonic tissue weight increased, and the plasma TNF- $\alpha$ , IL6, monocyte chemoattractant protein-1, IL1 $\beta$  and leptin levels significantly increased.<sup>105</sup> In children with IBD, intense exercise did not alter symptomatic outcomes or changes in serum inflammatory cytokines when compared with age-matched controls.<sup>106</sup> However, a recent systematic review of 637 patients (34% males) and pooled evidence from 6 randomized clinical trials found exercise improved disease activity but not disease-specific quality of life compared with controls.<sup>107</sup> Given that IBD is triggered by an abnormal immune response to the resident microbiota,<sup>108</sup> any effects of exercise on IBD likely impact the microbiome, although a systematic review of the systemic inflammatory response in exercise-based intervention studies in IBD patients reported no consistent effect.<sup>109</sup> A combination of exercise and psychological interventions in a group of patients with Crohn’s disease led to positive changes in their intestinal microbiome with accompanying reductions in systemic markers of inflammation.<sup>110</sup>



A recent meta-analysis concluded there was a reduced risk of developing IBD in individuals who undertook regular high- vs low-intensity PA.<sup>111</sup> However, early results from the IBD-FITT study ([ClinicalTrials.gov](https://clinicaltrials.gov/ct2/show/study/NCT04816812) NCT04816812), a RCT of 12 weeks of aerobic exercise in people with IBD,<sup>112</sup> show improvements in quality of life and other health-related outcomes, without any effect on disease activity.<sup>113</sup> These contrasting results suggest strong individual variation, with differences in the timing of the commencement of exercise training in relation to disease activity likely to be important. Fatigue, a major symptom in IBD patients, is associated with muscle deconditioning, with a small study showing patients with Crohn's disease exhibit impaired postexercise recovery, measured based on slower rates of muscle phosphocreatine resynthesis.<sup>114</sup> Although the links between PA, the microbiome, and disease outcomes in IBD remain unclear, sarcopenia is associated with poor clinical outcomes independent of IBD activity and, therefore, muscle health should be assessed in all IBD patients at routine intervals.<sup>54</sup>

In patients with irritable bowel syndrome (IBS), a disease without an easily measurable inflammatory response, symptoms are reduced after exercise training<sup>115,116</sup> and associated with exercise-induced improvements in gut motility along with favorable psychological changes. The first-line therapy for IBS is the low Fermentable Oligosaccharides, Disaccharides, Monosaccharides, and Polyols (FODMAP) diet,<sup>117</sup> which modulates its effect through direct dietary impact on the microbiome. As such, the benefit of exercise on IBS and other motility-related GI conditions may be mediated, in part, through the microbiome. A recent trial reporting fewer IBS symptoms after exercise training<sup>118</sup> also found that exercise reduced cell-free mitochondrial DNA in the plasma of the control (non-IBS) group.<sup>118,119</sup> Because mitochondrial DNA is a damage-associated molecular pattern that is bidirectionally associated with dysbiosis,<sup>120</sup> the results from that study suggest that PA can modify cellular damage-associated molecular patterns in healthy patients but not in IBS patients, which may be due to different microbial ecologies in those with IBS. A recent Cochrane review reported moderate positive outcomes of regular PA on IBS symptoms without clear improvement in quality of life,<sup>121</sup> again suggesting strong individual variation in such effects. Putative mechanisms that link the microbiome to effects of PA on IBS patients include changes to transit time, greater SCFA production, improvement in the intestinal barrier, as well as modulation of the immune response.<sup>122</sup>

## Exercise and GI Cancer Prevention: Molecular Mechanisms Related to the Microbiome

The protective effect of regular, moderate to vigorous PA against cancer risk is well established with evidence from epidemiologic studies, randomized controlled trials, and meta-analyses from cohort investigations showing that regular exercise reduces the risk of between 7 and 13 different cancers and cancer mortality, including less

frequent recurrence and fewer/less severe adverse effects.<sup>123–128</sup> Regular PA is inversely related to the risk of cancer at the proximal (relative risk [RR], 0.76; 95% confidence intervals [CI], 0.70–0.83) and distal colon (RR, 0.77; 95% CI, 0.71–0.83), although there is limited evidence for any positive effects of PA on reducing risk of rectal cancers (RR, 0.98; 95% CI, 0.88–1.08), indicating that different mechanisms are operating in the development of colon and rectal cancer.<sup>129</sup> The RR for gastroesophageal cancer is 0.82 (CI, 0.74–0.90).<sup>130</sup> The cancer for which regular PA confers the greatest protective effect is CRC,<sup>131–133</sup> with moderate levels of PA associated with a 25% reduction of CRCs and greater amounts of PA linked to a greater (40%) reduction in risk.<sup>134,135</sup> Even colorectal polyps can be reduced in number by increasing levels of PA.<sup>132,136</sup> After a year-long exercise training intervention in previously sedentary men who completed a minimum of 250 min/week of moderate-to vigorous-intensity exercise and whose  $VO_{2max}$  increased by >5%, there was a significant decrease in colon crypt proliferation and associated biomarkers (crypt height, number, and relative position of Ki67+ cells in stained cells in colon mucosal crypts) compared with nonexercising control subjects.<sup>132</sup> In an analyses of 48 studies that included 40,674 colon cancer/CRC cases, a graded inverse dose-response association was observed between PA and colon cancer for both sexes. This dose-response effect of physical activity on colon cancer risk was especially strong when patients performed activities of >4.5 metabolic equivalents (MET) vs <4.5 MET (where 1 MET is the resting metabolic rate equivalent to 3.5 mL O<sub>2</sub>/kg/min).<sup>135</sup> Of note, adjusting for potential confounding factors including age, diet, and obesity does not diminish the observed associations between levels of PA and colon cancer occurrence.<sup>132</sup> Exercise training has also been shown to reduce the risk of gastric cancer with individuals who are more physically active having a 19% lower incidence.<sup>137</sup> A similar prognostic effect was seen for esophageal cancer.<sup>138,139</sup> Given the range of similar risk reduction it appears likely that there is at least a degree of mechanistic crossover in the benefits in PA across GI cancers, with the mechanisms underpinning such effects being multifactorial. Here we focus on those mechanisms potentially related to muscle-microbiome cross-talk.

Over recent years, the use of immunotherapy in cancer treatment has highlighted the critical role of the immune system in cancer pathogenesis. The microbiome is intimately involved in the development of the immune system, especially in the GI tract.<sup>140,141</sup> Exercise induces a biphasic response in lymphocytes and mobilizes vascular, pulmonary, hepatic, and splenic white blood cells into the peripheral circulation. This initial lymphocytosis affects mainly natural killer (NK) cells, which increase several-fold above resting levels, with their mobilization proportional to the relative intensity of exercise. This response underpins adrenaline-stimulation of  $\beta$ 2-adrenergic receptors on the surface of lymphocytes leading to endothelial detachment and the subsequent recirculation of lymphocytes into the bloodstream. Blood lymphocyte count decrease 1–2 hours after exercise cessation with transient lymphopenia not



uncommon, although NK and T-cell counts return to baseline within 24 hours.<sup>142</sup> The precise mechanisms by which exercise-stimulated catecholamine signalling drive immune cell mobilization, redistribution, and function are not known, nor is the relationship by which this could be modified by changes in the microbiome.<sup>143</sup>

The immune-stimulating effects resulting from an acute bout of exercise persist for several hours and the use of exercise-stimulated T cells to augment the volume of cells that could be used for adoptive transfer into lymphopenic patients has been discussed elsewhere.<sup>15</sup> However, it is the chronic effects of the progressive accumulation of frequent acute challenges that are likely to play regulatory roles in tumor growth kinetics and tumor metabolism, through their effects of immune function in general, and on antitumor immune function specifically.<sup>15</sup> In rodents, a program of voluntary wheel running for 2 months was linked to improved antitumorigenic function through an increase in splenic NK cell cytotoxic function, an effect that persisted 3 weeks after the training intervention ceased.<sup>144</sup> A similar immune response has been reported in humans with Lynch syndrome (a hereditary condition with a high lifetime risk of CRCs and endometrial cancers), where chronic (12 months) exercise training decreased inflammatory markers (prostaglandin E) in colon and blood and increased the colonic mucosa levels of NK and CD8+ T cells in the exercise-trained patients.<sup>145</sup> These findings have important implications for cancer interventions in patients with Lynch syndrome because they demonstrate the beneficial biological effects of exercise in the immune system of a target organ in patients at risk for cancer. Given the relationship between mucosal immunity and the microbiome,<sup>146</sup> it is conceivable that such an effect may be mediated through intestinal microbiota.

While PA modulates pathways regulating local and systemic inflammation and oxidative stress,<sup>126</sup> exercise-induced activation/suppression of pathways that sense and regulate energy availability, cellular metabolism, tumor development, proliferation, metastasis, and cytoskeleton organization are also important in conferring the protective effect of PA. These pathways include the AMP-activated protein kinase (AMPK) and the Akt/mammalian target of rapamycin (mTOR) pathways. The targets of these signalling nodes include many transcription factors, coactivators, and repressors<sup>13</sup> with all of these pathways potentially modified by alternations in the gut microbiome. Indeed, a growing body of evidence supports the beneficial effects of AMPK on gut health, such as enhancing intestinal absorption, improving barrier function, suppressing colorectal carcinogenesis, and reducing intestinal inflammation and metabolic-related disease states. Conversely, AMPK is inhibited under conditions of obesity and diabetes, both of which are correlated with impaired intestinal barrier function.<sup>147</sup>

The AMPK pathway is activated in tumors in response to an acute bout of PA, although exercise training may inhibit carcinogenesis by suppressing the activation of the mTOR signaling network in carcinomas, an effect mediated through effects of PA on circulating growth factors and hormones

that regulate the mTOR network that are distinct from those affecting mTOR activity in contracting skeletal muscle.<sup>148</sup> Although this premise has some mechanistic basis, no studies have fully elucidated the direct effects of mTOR signalling on tumor growth in humans.<sup>149</sup> Tumors have altered cellular metabolism that favors aerobic glycolysis to support the high energy turnover and rapid cell proliferation. Accordingly, intratumoral metabolism will be impacted by whole-body PA, with results from preclinical studies suggesting that tumors with intrinsically high metabolism are susceptible to exercise-induced energy depletion. Such shifts in metabolism induced by exercise modulate the metabolic reprogramming that occurs during carcinogenesis to support cell growth and proliferation, and suggest that carcinogenesis can be inhibited or enhanced by effects on intermediary metabolism linked to PA and dependent on exercise intensity and duration. A recent example in CRC patients provided mechanistic insights into PA impact on tumor growth. In large CRC datasets, RPS4X expression (related to “stemness”), which is associated with metastases and poor outcomes, is down-regulated with exercise.<sup>150</sup> Given the relationship between the microbiome and stem cell regulation in the intestine, it is feasible that exercise may influence CRC risk via this pathway. This makes CRC a potential early candidate for combining microbiome modulation with PA in improving clinical outcomes.

Another potential mechanism for the beneficial effects of regular exercise on CRC risk and tumor growth is the training-induced increase in SCFA production. CRC patients typically present with a compromised gut microbiota characterized by a reduced abundance of butyrate-producing taxa, including *Roseburia* and *Lachnospiraceae*. Results from *in vitro* studies demonstrate that butyrate differentially regulates gene expression in healthy vs cancerous cells.<sup>151</sup> In healthy epithelial cells, butyrate is rapidly metabolized via the mitochondrial TCA cycle, causing in the accumulation of cytosolic citrate and acetyl CoA, thus increasing the acetylation of histones by histone acetyltransferases. This epigenetic modification increases expression of genes involved in cell proliferation and cell turnover, strengthening the intestinal barrier. However, in CRC cells, mitochondrial dysfunction results in the accumulation of butyrate in the cytosol. This free butyrate inhibits histone deacetylases, resulting in the epigenetic suppression of proliferation and promotion of cell death pathways that may lead to a reduction in tumor size and reduces the chance of metastasis.<sup>151</sup>

## Human Microbiome Research: Current Perspectives and Directions for Future Research

The benefits of regular PA in preventing and/or treating numerous NCDs have been known for centuries. However, the precise mechanisms by which exercise training defends and protects the body against a range of lifestyle-induced diseases have not been elucidated. The discovery that contracting skeletal muscle is an endocrine organ acting as the primary metabolic communicator for interorgan

communication provides a plausible mechanism by which exercise training boosts immunity at both the whole-body and local (tissue) level. Although regular PA facilitates a more diverse gut microbiome and functional metabolome with direct and variable effects on GI disease outcomes, the precise dose of exercise necessary to induce favorable changes in the gut microbiome and enhance host immunity is unknown. Although “excessive” PA can have detrimental effects on intestinal barrier integrity, these are transient and benign. The gut microbiome, therefore, is an attractive target for modulating many of the positive effects of exercise on GI health and disease with the links between certain GI microbiota and the disease states of peripheral tissues/organs making microbial modulation a potentially potent immunotherapeutic therapy.

Current evidence indicates that a certain level of hormesis is necessary to perturb the human gut microbiota, with exercise interventions lasting a minimum of 2–3 months needed to produce consistent changes across alpha and beta diversity and most genera,<sup>34</sup> although some of the observable modifications in gut microbiota occur 2–4 weeks after the onset of an appropriate exercise stimulus.<sup>34</sup> As noted previously,<sup>61</sup> the beneficial effects of exercise training on the gut microbiota are rapidly reversed after several weeks of inactivity in both lean and obese individuals, a similar time-course of loss of adaptation observed in patients with celiac disease.<sup>152</sup> In athletes with a prolonged history of exercise training, the alpha-diversity and global composition of the gut microbiome remain unaffected by 3 weeks of reduced exercise,<sup>153</sup> suggesting that changes in exercise volume have less of an impact on individuals with a background of regular PA. However, the duration (months or years) of regular PA required to establish “steady-state” homeostasis in the gut microbiome that persists in the face of the removal of an exercise stimulus is unknown.

There remain many challenges facing microbiome science with several fundamental questions still remaining. For example, much of the observed interindividual differences in the gut microbiome can be attributed to the fact that some parts of the total microbiome remain poorly characterized, with their biological significance largely unknown. Nevertheless, an emerging area with potential clinical significance to improve host health are a number of microbial interventions, including fecal microbiota transfer (FMT). A recent study examined the effects of FMT from exercised-trained mice to germ-free animals.<sup>154</sup> Fecal samples from sedentary and trained animals were gavaged into germ-free mice. After receiving fecal samples from trained donor mice, recipient mice had elevated levels of AMPK and insulin-like growth factor-1 in skeletal muscle along with improved whole-body glycemia and insulin sensitivity, effects that were mediated, in part, by the anti-inflammatory properties of bile acid deconjugation. This study concluded that FMT mimics the health-promoting effects of exercise by inducing critical exercise-inducible signal transduction pathways in skeletal muscle, thereby improving metabolic health through the “muscle and gut axis.”<sup>154</sup> Other studies in murine models of obesity also demonstrate that the beneficial effects of both exercise and diet are transmissible via

FMT.<sup>155</sup> In humans, FMT involves the infusion of feces from a healthy donor to the GI tract of a recipient patient with the aim of treating diseases associated with alteration of gut microbiota. Although the results from several rodent studies reveal positive outcomes of FMT from both exercise- or diet-manipulated donor animals to germ-free mice on several health markers,<sup>154,155</sup> data from FMT in humans is lacking for the majority of GI-related disease states. Indeed, consistent with a European consensus conference on FMT in clinical practice,<sup>156</sup> *Clostridium difficile* infection is the only indication where market authorization for FMT has been achieved.

There are several exciting clinical opportunities in microbiome science with the recent application of a host of molecular techniques offering the potential for a greater understanding of the multiplicity and complexity of networks involved in exercise responses and on the mechanisms by which muscle “communicates” with the GI tract to mediate many of the beneficial effects of PA. While the structural characteristics of the gut microbiota have been described through the application of 16S rRNA amplicon sequencing,<sup>157</sup> next-generation sequencing techniques and the creation and integration of functional ‘omics readouts (ie, metatranscriptomics, metaproteomics, and metabolomics) will provide more accurate assessment of health and disease states and provide a basis for functional and experimental validation. This is essential as up to 85% of the variance within the human microbiome from population-based studies is still unaccounted.<sup>57</sup> For example, in a longitudinal study of patients with Crohn’s disease (n = 303) and ulcerative colitis (n = 228), most of the compositional variance of the gut microbiota remained unexplained.<sup>158</sup>

Resetting gut microbiome-derived signals of “unhealthy” ageing through personalized or subpopulation-level microbiome-associated interventions is a promising area of research that will be informed by large shotgun metagenomics-based studies and data analytics coupled with preclinical experimental models. Resulting microbiome-based therapeutics for the elderly will need a combination of therapies, including dietary intervention with microbial restoration of lost strains.<sup>159</sup> The identification of microbial profiles in middle-age that confer increased disease risk later in life (eg, biomarkers for colon cancer) present a formidable clinical challenge that will be confounded by the loss of dietary diversity with age, along with the associated decrease of microbiota diversity accompanied by increased risk of inflammation.<sup>160</sup> Levels of habitual PA also decrease with age<sup>161</sup> and are associated with sarcopenia and loss of function.<sup>160</sup> The influence of these lifestyle factors on modifying microbiome composition and controlling for them in large-scale human studies presents a huge challenge when trying to unravel the mechanisms underpinning the therapeutic effects of PA and diet interventions on the gut microbiota, and will require integration of large multicenter cohorts, advanced ‘omics technologies and sophisticated experimental validations of the mechanistic associations identified.

Increasing evidence demonstrates the association of specific taxa in the development of certain GI diseases

including many cancers; altering the composition of the gut microbiota to improve the efficacy of anticancer drugs may be a feasible intervention in the future. Interindividual differences in patients' treatment-naïve gut microbiome may play a role in the efficacy of the hosts response to certain therapies, analogous to "low vs high responders" to exercise training interventions. Another exciting area for future research is gaining a better understanding of the relationship between gut microbiota, skeletal muscle mass, and physical function<sup>162</sup> particularly during ageing, which is associated with reduced microbiota biodiversity, increased interindividual variability, lower representation of butyrate-producing bacteria, and over-representation of pathobionts.<sup>163</sup> Reduced muscle mass has been associated with distinct microbiota composition and reduced fermentive capacity in mice, with the administration of probiotics and butyrate to mouse models of muscle wasting, associated with improved muscle mass.<sup>162</sup> Especially promising are the results from preclinical data showing that colonization of mice with gut microbiota from exercise-trained mice attenuated the response to chemically induced colitis, reduced colon shortening, attenuated mucus depletion, and augmented expression of cytokines involved in tissue regeneration.<sup>164</sup> As such, future efforts should concentrate on gaining a deeper understanding of the factors involved in exercise-gut interactions through the application of advanced techniques to measure both the microbiome and the systemic effects of exercise in a variety of diseased populations. It is hoped that future therapies to treat a range of GI-related disorders, including cancers, will be based on a growing recognition that regular PA can positively modify the human gut microbiome, boost immunity, and decrease the incidence, progression, and personal burden of these NCDs. As such, it is recommended that regular PA be incorporated into standard clinical treatment protocols for individuals with several GI-related diseases.

## References

- Blair SN, Kohl HW 3rd, Paffenbarger RS Jr, et al. Physical fitness and all-cause mortality. A prospective study of healthy men and women. *JAMA* 1989;262:2395–2401.
- Booth FW, Chakravarthy MV, Gordon SE, et al. Waging war on physical inactivity: using modern molecular ammunition against an ancient enemy. *J Appl Physiol* (1985) 2002;93:3–30.
- Kodama S, Saito K, Tanaka S, et al. Cardiorespiratory fitness as a quantitative predictor of all-cause mortality and cardiovascular events in healthy men and women: a meta-analysis. *JAMA* 2009;301:2024–2035.
- Pedersen BK, Saltin B. Evidence for prescribing exercise as therapy in chronic disease. *Scand J Med Sci Sports* 2006;16(Suppl 1):3–63.
- Pedersen BK, Saltin B. Exercise as medicine - evidence for prescribing exercise as therapy in 26 different chronic diseases. *Scand J Med Sci Sports* 2015;25(Suppl 3):1–72.
- Rueggsegger GN, Booth FW. Health benefits of exercise. *Cold Spring Harb Perspect Med* 2018;8.
- Cormie P, Trevaskis M, Thornton-Benko E, et al. Exercise medicine in cancer care. *Aust J Gen Pract* 2020; 49:169–174.
- Czosnek L, Rankin NM, Cormie P, et al. "Now is the time for institutions to be investing in growing exercise programs as part of standard of care": a multiple case study examining the implementation of exercise oncology interventions. *Support Care Cancer* 2023;31:422.
- Ross R, Blair SN, Arena R, et al. Importance of assessing cardiorespiratory fitness in clinical practice: a case for fitness as a clinical vital sign: a scientific statement from the American Heart Association. *Circulation* 2016; 134:e653–e699.
- Sallis RE. Exercise is medicine and physicians need to prescribe it. *Br J Sports Med* 2009;43:3–4.
- Schmitz KH, Campbell AM, Stuver MM, et al. Exercise is medicine in oncology: engaging clinicians to help patients move through cancer. *CA Cancer J Clin* 2019; 69:468–484.
- Neufer PD, Bamman MM, Muoio DM, et al. Understanding the cellular and molecular mechanisms of physical activity-induced health benefits. *Cell Metab* 2015;22:4–11.
- Hawley JA, Hargreaves M, Joyner MJ, et al. Integrative biology of exercise. *Cell* 2014;159:738–749.
- Cerda B, Perez M, Perez-Santiago JD, et al. Gut microbiota modification: another piece in the puzzle of the benefits of physical exercise in health? *Front Physiol* 2016;7:51.
- Fiuzza-Luces C, Valenzuela PL, Gálvez BG, et al. The effect of physical exercise on anticancer immunity. *Nat Rev Immunol* 2024;24:282–293.
- Sales KM, Reimer RA. Unlocking a novel determinant of athletic performance: the role of the gut microbiota, short-chain fatty acids, and "biotics" in exercise. *J Sport Health Sci* 2023;12:36–44.
- Mailing LJ, Allen JM, Buford TW, et al. Exercise and the gut microbiome: a review of the evidence, potential mechanisms, and implications for human health. *Exerc Sport Sci Rev* 2019;47:75–85.
- Beresford-Jones BS, Forster SC, Stares MD, et al. The mouse gastrointestinal bacteria catalogue enables translation between the mouse and human gut microbiotas via functional mapping. *Cell Host Microbe* 2022; 30:124–138.e8.
- Hawley JA, Sassone-Corsi P, Zierath JR. Chrono-nutrition for the prevention and treatment of obesity and type 2 diabetes: from mice to men. *Diabetologia* 2020; 63:2253–2259.
- Boyatar AN, Nitert MD, Morrisson M, et al. Exercise-induced changes to the human gut microbiota and implications for colorectal cancer: a narrative review. *J Physiol* 2022;600:5189–5201.
- Rosshart SP, Herz J, Vassallo BG, et al. Laboratory mice born to wild mice have natural microbiota and model human immune responses. *Science* 2019;365: eaaw4361.
- Mirzaei R, Afaghi A, Babakhani S, et al. Role of microbiota-derived short-chain fatty acids in cancer development and prevention. *Biomed Pharmacother* 2021;139:111619.



23. Hart NH, Wallen MP, Farley MJ, et al. Exercise and the gut microbiome: implications for supportive care in cancer. *Support Care Cancer* 2023;31:724. 1201 1202 1203 1204 1205 1206 1207 1208 1209 1210 1211 1212 1213 1214 1215 1216 1217 1218 1219 1220 1221 1222 1223 1224 1225 1226 1227 1228 1229 1230 1231 1232 1233 1234 1235 1236 1237 1238 1239 1240 1241 1242 1243 1244 1245 1246 1247 1248 1249 1250 1251 1252 1253 1254 1255 1256 1257 1258 1259 1260
24. Sepich-Poore GD, Zitvogel L, Straussman R, et al. The microbiome and human cancer. *Science* 2021;371.
25. Murphy RM, Watt MJ, Febbraio MA. Metabolic communication during exercise. *Nat Metab* 2020; 2:805–816.
26. Goldstein MS. Humoral nature of the hypoglycemic factor of muscular work. *Diabetes* 1961;10:232–234.
27. Febbraio MA, Pedersen BK. Muscle-derived interleukin-6: mechanisms for activation and possible biological roles. *FASEB J* 2002;16:1335–1347.
28. Pedersen BK, Febbraio MA. Muscle as an endocrine organ: focus on muscle-derived interleukin-6. *Physiol Rev* 2008.
29. Whitham M, Febbraio MA. The ever-expanding myokine: discovery challenges and therapeutic implications. *Nat Rev Drug Discov* 2016;15:719–729.
30. Weigert C, Hoene M, Plomgaard P. Hepatokines—a novel group of exercise factors. *Pflugers Arch* 2019; 471:383–396.
31. Roca-Rivada A, Al-Massadi O, Castela C, et al. Muscle tissue as an endocrine organ: comparative secretome profiling of slow-oxidative and fast-glycolytic rat muscle explants and its variation with exercise. *J Proteom* 2012; 75:5414–5425.
32. Cook MD, Allen JM, Pence BD, et al. Exercise and gut immune function: evidence of alterations in colon immune cell homeostasis and microbiome characteristics with exercise training. *Immunol Cell Biol* 2016; 94:158–163.
33. Monda V, Villano I, Messina A, et al. Exercise modifies the gut microbiota with positive health effects. *Oxidative Med Cellular Longevity* 2017;2017:3831972.
34. Boytar AN, Skinner TL, Wallen RE, et al. The effect of exercise prescription on the human gut microbiota and comparison between clinical and apparently healthy populations: a systematic review. *Nutrients* 2023; 15:1534.
35. Okamoto T, Morino K, Ugi S, et al. Microbiome potentiates endurance exercise through intestinal acetate production. *Am J Physiol Endocrinol Metab* 2019; 316:E956–E966.
36. Hawley JA. Microbiota and muscle highway - two way traffic. *Nat Rev Endocrinol* 2020;16:71–72.
37. Allen JM, Berg Miller ME, Pence BD, et al. Voluntary and forced exercise differentially alters the gut microbiome in c57bl/6j mice. *J Appl Physiol* (1985) 2015; 118:1059–1066.
38. Matsumoto M, Inoue R, Tsukahara T, et al. Voluntary running exercise alters microbiota composition and increases n-butyrate concentration in the rat cecum. *Bio-sci Biotechnol Biochem* 2008;72:572–576.
39. Lambert JE, Myslicki JP, Bomhof MR, et al. Exercise training modifies gut microbiota in normal and diabetic mice. *Appl Physiol Nutr Metab* 2015; 40:749–752.
40. Gill RK, Saksena S, Alrefai WA, et al. Expression and membrane localization of mct isoforms along the length of the human intestine. *Am J Physiol Cell Physiol* 2005; 289:C846–C852. 1261 1262 1263 1264 1265 1266 1267 1268 1269 1270 1271 1272 1273 1274 1275 1276 1277 1278 1279 1280 1281 1282 1283 1284 1285 1286 1287 1288 1289 1290 1291 1292 1293 1294 1295 1296 1297 1298 1299 1300 1301 1302 1303 1304 1305 1306 1307 1308 1309 1310 1311 1312 1313 1314 1315 1316 1317 1318 1319 1320
41. Peng L, Li ZR, Green RS, et al. Butyrate enhances the intestinal barrier by facilitating tight junction assembly via activation of amp-activated protein kinase in caco-2 cell monolayers. *J Nutr* 2009;139:1619–1625.
42. Lahiri S, Kim H, Garcia-Perez I, et al. The gut microbiota influences skeletal muscle mass and function in mice. *Sci Transl Med* 2019;11:eaan5662.
43. Mirzaei R, Dehkhodaie E, Bouzari B, et al. Dual role of microbiota-derived short-chain fatty acids on host and pathogen. *Biomed Pharmacother* 2022;145:112352.
44. Clarke SF, Murphy EF, O’Sullivan O, et al. Exercise and associated dietary extremes impact on gut microbial diversity. *Gut* 2014;63:1913–1920.
45. Estaki M, Pither J, Baumeister P, et al. Cardiorespiratory fitness as a predictor of intestinal microbial diversity and distinct metagenomic functions. *Microbiome* 2016;4:42.
46. Barton W, Penney NC, Cronin O, et al. The microbiome of professional athletes differs from that of more sedentary subjects in composition and particularly at the functional metabolic level. *Gut* 2018;67:625–633.
47. Kulecka M, Fraczek B, Mikula M, et al. The composition and richness of the gut microbiota differentiate the top polish endurance athletes from sedentary controls. *Gut Microbes* 2020;11:1374–1384.
48. Himbert C, Stephens WZ, Gigic B, et al. Differences in the gut microbiome by physical activity and BMI among colorectal cancer patients. *Am J Cancer Res* 2022; 12:4789–4801.
49. Wirbel J, Pyl PT, Kartal E, et al. Meta-analysis of fecal metagenomes reveals global microbial signatures that are specific for colorectal cancer. *Nat Med* 2019; 25:679–689.
50. Scheiman J, Luber JM, Chavkin TA, et al. Meta-omics analysis of elite athletes identifies a performance-enhancing microbe that functions via lactate metabolism. *Nat Med* 2019;25:1104–1109.
51. Ahn J, Sinha R, Pei Z, et al. Human gut microbiome and risk for colorectal cancer. *J Natl Cancer Inst* 2013; 105:1907–1911.
52. Ott SJ, Musfeldt M, Wenderoth DF, et al. Reduction in diversity of the colonic mucosa associated bacterial microflora in patients with active inflammatory bowel disease. *Gut* 2004;53:685–693.
53. Dasarathy S, Merli M. Sarcopenia from mechanism to diagnosis and treatment in liver disease. *J Hepatol* 2016; 65:1232–1244.
54. Gold SL, Raman M, Sands BE, et al. Putting some muscle into sarcopenia—the pathogenesis, assessment and clinical impact of muscle loss in patients with inflammatory bowel disease. *Aliment Pharmacol Ther* 2023;57:1216–1230.
55. Aragon-Vela J, Solis-Urra P, Ruiz-Ojeda FJ, et al. Impact of exercise on gut microbiota in obesity. *Nutrients* 2021;13.
56. Mohr AE, Jager R, Carpenter KC, et al. The athletic gut microbiota. *J Int Soc Sports Nutr* 2020;17:24.
57. Shanahan F, Ghosh TS, O’Toole PW. The healthy microbiome—what is the definition of a healthy gut microbiome? *Gastroenterology* 2021;160:483–494.



- 1321 58. Cataldi S, Bonavolontà V, Poli L, et al. The relationship  
1322 between physical activity, physical exercise, and human  
1323 gut microbiota in healthy and unhealthy subjects: a  
1324 systematic review. *Biology* 2022;11:479. 1381
- 1325 59. Clark A, Mach N. Exercise-induced stress behavior, gut-  
1326 microbiota-brain axis and diet: a systematic review for  
1327 athletes. *J Int Soc Sports Nutr* 2016;13:43. 1382
- 1328 60. Bonomini-Gnutzmann R, Plaza-Diaz J, Jorquera-  
1329 Aguilera C, et al. Effect of intensity and duration of ex-  
1330 ercise on gut microbiota in humans: a systematic review.  
1331 *Int J Environ Res Public Health* 2022;19:9518. 1383
- 1332 61. Allen JM, Mailing LJ, Niemi GM, et al. Exercise alters  
1333 gut microbiota composition and function in lean and  
1334 obese humans. *Med Sci Sports Exerc* 2018;50:747–757. 1384
- 1335 62. Mc Gettigan N, Allen K, Saeidi R, et al. A systematic  
1336 review of the effect of structured exercise on inflamma-  
1337 tion and body composition in inflammatory bowel dis-  
1338 ease. *Int J Colorectal Dis* 2023;38:143. 1385
- 1339 63. Mc Gettigan N, O'Toole A, Boland K. "Role of exercise in  
1340 preventing and restoring gut dysbiosis in patients with  
1341 inflammatory bowel disease": a letter to the editor. *World  
1342 J Gastroenterol* 2022;28:878–880. 1386
- 1343 64. Horner KM, Schubert MM, Desbrow B, et al. Acute ex-  
1344 ercise and gastric emptying: a meta-analysis and impli-  
1345 cations for appetite control. *Sports Med* 2015;  
1346 45:659–678. 1387
- 1347 65. van Wijck K, Pennings B, van Bijnen AA, et al. Dietary  
1348 protein digestion and absorption are impaired during  
1349 acute postexercise recovery in young men. *Am J Physiol  
1350 Regul Integr Comp Physiol* 2013;304:R356–R361. 1388
- 1351 66. Lang JA, Gisolfi CV, Lambert GP. Effect of exercise in-  
1352 tensity on active and passive glucose absorption. *Int J  
1353 Sport Nutr Exerc Metab* 2006;16:485–493. 1389
- 1354 67. Schmitz L, Ferrari N, Schwiertz A, et al. Impact of  
1355 endurance exercise and probiotic supplementation on  
1356 the intestinal microbiota: a cross-over pilot study. *Pilot  
1357 Feasibility Stud* 2019;5:76. 1390
- 1358 68. Costa RJ, Snipe R, Camoes-Costa V, et al. The impact of  
1359 gastrointestinal symptoms and dermatological injuries  
1360 on nutritional intake and hydration status during ultra-  
1361 marathon events. *Sports Med Open* 2016;2:16. 1391
- 1362 69. ter Steege RW, Van der Palen J, Kolkman JJ. Prevalence  
1363 of gastrointestinal complaints in runners competing in a  
1364 long-distance run: an internet-based observational study  
1365 in 1281 subjects. *Scand J Gastroenterol* 2008;  
1366 43:1477–1482. 1392
- 1367 70. De Oliveira EP, Burini RC. Carbohydrate-dependent,  
1368 exercise-induced gastrointestinal distress. *Nutrients*  
1369 2014;6:4191–4199. 1393
- 1370 71. Grootjans J, Lenaerts K, Buurman WA, et al. Life and  
1371 death at the mucosal-luminal interface: new perspec-  
1372 tives on human intestinal ischemia-reperfusion. *World J  
1373 Gastroenterol* 2016;22:2760–2770. 1394
- 1374 72. ter Steege RW, Kolkman JJ. Review article: the patho-  
1375 physiology and management of gastrointestinal symp-  
1376 toms during physical exercise, and the role of splanchnic  
1377 blood flow. *Aliment Pharmacol Ther* 2012;35:516–528. 1395
- 1378 73. Dokladny K, Zuhl MN, Moseley PL. Intestinal epithelial  
1379 barrier function and tight junction proteins with heat and  
1380 exercise. *J Appl Physiol (1985)* 2016;120:692–701. 1396
74. Zuhl M, Schneider S, Lanphere K, et al. Exercise regu-  
1382 lation of intestinal tight junction proteins. *Br J Sports  
1383 Med* 2014;48:980–986. 1397
75. van Wijck K, Lenaerts K, van Loon LJ, et al. Exercise-  
1384 induced splanchnic hypoperfusion results in gut  
1385 dysfunction in healthy men. *PLoS One* 2011;6:e22366. 1398
76. Bosenberg AT, Brock-Utne JG, Gaffin SL, et al. Stren-  
1386 uous exercise causes systemic endotoxemia. *J Appl  
1387 Physiol (1985)* 1988;65:106–108. 1399
77. Camus G, Poortmans J, Nys M, et al. Mild endotoxaemia  
1388 and the inflammatory response induced by a marathon  
1389 race. *Clin Sci (Lond)* 1997;92:415–422. 1400
78. Gill SK, Teixeira A, Rama L, et al. Circulatory endotoxin  
1390 concentration and cytokine profile in response to  
1391 exertional-heat stress during a multi-stage ultra-mara-  
1392 thon competition. *Exerc Immunol Rev* 2015;21:114–128. 1401
79. Gill SK, Hankey J, Wright A, et al. The impact of a 24-h  
1393 ultra-marathon on circulatory endotoxin and cytokine  
1394 profile. *Int J Sports Med* 2015;36:688–695. 1402
80. Robertson JD, Maughan RJ, Davidson RJ. Faecal blood  
1395 loss in response to exercise. *Br Med J (Clin Res Ed)*  
1396 1987;295:303–305. 1403
81. Tota L, Piotrowska A, Palka T, et al. Muscle and intestinal  
1397 damage in triathletes. *PLoS One* 2019;14:e0210651. 1404
82. Pals KL, Chang RT, Ryan AJ, et al. Effect of running  
1398 intensity on intestinal permeability. *J Appl Physiol (1985)*  
1399 1997;82:571–576. 1405
83. Roca Rubio MF, Folkesson M, Kremp C, et al. Associ-  
1400 ations between various markers of intestinal barrier and  
1401 immune function after a high-intensity exercise chal-  
1402 lenge. *Physiol Rep* 2024;12:e16087. 1406
84. Jeukendrup AE. Training the gut for athletes. *Sports Med*  
1403 2017;47:101–110. 1407
85. Burke LM, Hawley JA. Swifter, higher, stronger: what's  
1404 on the menu? *Science* 2018;362:781–787. 1408
86. Costa RJS, Snipe RMJ, Kitic CM, et al. Systematic re-  
1405 view: exercise-induced gastrointestinal syndrome-  
1406 implications for health and intestinal disease. *Aliment  
1407 Pharmacol Ther* 2017;46:246–265. 1409
87. Rehrer NJ, Goes E, DuGardeyn C, et al. Effect of car-  
1408 bohydrate on portal vein blood flow during exercise. *Int J  
1409 Sports Med* 2005;26:171–176. 1410
88. Costa RJS, Miall A, Khoo A, et al. Gut-training: the  
1410 impact of two weeks repetitive gut-challenge during  
1411 exercise on gastrointestinal status, glucose availability,  
1412 fuel kinetics, and running performance. *Appl Physiol Nutr  
1413 Metab* 2017;42:547–557. 1414
89. Houghton MJ, Snipe RMJ, Williamson G, et al. Plasma  
1414 measurements of the dual sugar test reveal carbohy-  
1415 drate immediately alleviates intestinal permeability  
1416 caused by exertional heat stress. *J Physiol* 2023;  
1417 601:4573–4589. 1418
90. Scrivin R, Slater G, Mika A, et al. The impact of 48 h high  
1418 carbohydrate diets with high and low FODMAP content  
1419 on gastrointestinal status and symptoms in response to  
1420 endurance exercise, and subsequent endurance perfor-  
1421 mance. *Appl Physiol Nutr Metab* 2024;49:773–791. 1419
91. Lis D, Stellingwerff T, Kitic CM, et al. No effects of a  
1422 short-term gluten-free diet on performance in nonceliac  
1423 athletes. *Med Sci Sports Exerc* 2015;47:2563–2570. 1420

- 1441 92. Buchman AL, O'Brien W, Ou CN, et al. The effect of  
1442 arginine or glycine supplementation on gastrointestinal  
1443 function, muscle injury, serum amino acid concentra-  
1444 tions and performance during a marathon run. *Int J*  
1445 *Sports Med* 1999;20:315–321.
- 1446 93. van Wijck K, Wijnands KA, Meesters DM, et al. L-citrulline  
1447 improves splanchnic perfusion and reduces gut injury  
1448 during exercise. *Med Sci Sports Exerc* 2014;46:  
1449 2039–2046.
- 1450 94. Shing CM, Peake JM, Lim CL, et al. Effects of probiotics  
1451 supplementation on gastrointestinal permeability,  
1452 inflammation and exercise performance in the heat. *Eur J*  
1453 *Appl Physiol* 2014;114:93–103.
- 1454 95. Lamprecht M, Bogner S, Schippinger G, et al. Probiotic  
1455 supplementation affects markers of intestinal barrier,  
1456 oxidation, and inflammation in trained men; a random-  
1457 ized, double-blinded, placebo-controlled trial. *J Int Soc*  
1458 *Sports Nutr* 2012;9:45.
- 1459 96. Wang L, Meng FJ, Jin YH, et al. Effects of probiotic  
1460 supplementation on 12 min run performance, mood  
1461 management, body composition and gut microbiota in  
1462 amateur marathon runners: a double-blind controlled  
1463 trial. *J Exerc Sci Fit* 2024;22:297–304.
- 1464 97. Lennon S, Lackie T, Miltko A, et al. Safety and efficacy of  
1465 a probiotic cocktail containing *P. acidilactici* and *L.*  
1466 *plantarum* for gastrointestinal discomfort in endurance  
1467 runners: randomized double-blinded crossover clinical  
1468 trial. *Appl Physiol Nutr Metab* 2024;49:890–903.
- 1469 98. Gill SK, Allerton DM, Ansley-Robson P, et al. Does short-  
1470 term high dose probiotic supplementation containing  
1471 *Lactobacillus casei* attenuate exertional-heat stress  
1472 induced endotoxaemia and cytokinaemia? *Int J Sport*  
1473 *Nutr Exerc Metab* 2016;26:268–275.
- 1474 99. Pyne DB, West NP, Cox AJ, et al. Probiotics supple-  
1475 mentation for athletes—clinical and physiological effects.  
1476 *Eur J Sport Sci* 2015;15:63–72.
- 1477 100. American College of Sports Medicine. Physical activity  
1478 guidelines, 2019.
- 1479 101. Younossi ZM, Corey KE, Lim JK. Aa clinical practice  
1480 update on lifestyle modification using diet and exercise  
1481 to achieve weight loss in the management of nonalco-  
1482 holic fatty liver disease: expert review. *Gastroenterology*  
1483 2021;160:912–918.
- 1484 102. Benede-Ubieto R, Cubero FJ, Nevzorova YA. Breaking  
1485 the barriers: the role of gut homeostasis in metabolic-  
1486 associated steatotic liver disease (masld). *Gut Mi-*  
1487 *crobes* 2024;16:2331460.
- 1488 103. Hughes A, Dahmus J, Rivas G, et al. Exercise training  
1489 reverses gut dysbiosis in patients with biopsy-proven  
1490 nonalcoholic steatohepatitis: a proof of concept study.  
1491 *Clin Gastroenterol Hepatol* 2021;19:1723–1725.
- 1492 104. Kaplan GG. The global burden of ibd: from 2015 to 2025.  
1493 *Nat Rev Gastroenterol Hepatol* 2015;12:720–727.
- 1494 105. Bilski J, Mazur-Bialy A, Brzozowski B, et al. Can exercise  
1495 affect the course of inflammatory bowel disease?  
1496 Experimental and clinical evidence. *Pharmacol Rep*  
1497 2016;68:827–836.
- 1498 106. Ploeger H, Obeid J, Nguyen T, et al. Exercise and  
1499 inflammation in pediatric Crohn's disease. *Int J Sports*  
1500 *Med* 2012;33:671–679.
- 1501 107. Jones K, Kimble R, Baker K, et al. Effects of structured  
1502 exercise programmes on physiological and psychologi-  
1503 cal outcomes in adults with inflammatory bowel disease  
1504 (ibd): a systematic review and meta-analysis. *PLoS One*  
1505 2022;17:e0278480.
- 1506 108. Manichanh C, Borruel N, Casellas F, et al. The gut  
1507 microbiota in ibd. *Nat Rev Gastroenterol Hepatol* 2012;  
1508 9:599–608.
- 1509 109. Baker KA, Miller TD, Marino FE, et al. The exercise-  
1510 induced inflammatory response in inflammatory bowel  
1511 disease: a systematic review and meta-analysis. *PLoS*  
1512 *One* 2022;17:e0262534.
- 1513 110. Ilan K, Motro Y, Nemirovsky A, et al. Cognitive behavioral  
1514 and mindfulness with daily exercise intervention is  
1515 associated with changes in intestinal microbial taxa and  
1516 systemic inflammation in patients with Crohn's disease.  
1517 *Gut Microbes* 2024;16:2337269.
- 1518 111. Tiong HT, Fan D, Frampton C, et al. Physical activity is  
1519 associated with a decreased risk of developing inflam-  
1520 matory bowel disease: a systematic review and meta-  
1521 analysis. *J Crohn's Colitis* 2024;jjaa053.
- 1522 112. Lund K, Knudsen T, Kjeldsen J, et al. The ibd-fitt study -  
1523 moderate-intensity exercise for patients with inflammatory  
1524 bowel disease with moderate disease activity: an open-  
1525 label randomized controlled trial. *Trials* 2023;24:742.
- 1526 113. Van De Pol N, Visser E, van der Woude C, et al. P744  
1527 evaluation of a lifestyle program based on physical ac-  
1528 tivity on quality of life and fatigue in patients with in-  
1529 flammatory bowel disease: a pilot study. *J Crohn's*  
1530 *Colitis* 2024;18:i1393–i1394.
- 1531 114. McGing JJ, Serres S, Nicholas R, et al. Deconditioning in  
1532 quiescent Crohn's disease patients with heightened fa-  
1533 tigue perception. *J Crohn's Colitis* 2025;jjaa194.
- 1534 115. Johannesson E, Simren M, Strid H, et al. Physical activity  
1535 improves symptoms in irritable bowel syndrome: a ran-  
1536 domized controlled trial. *Am J Gastroenterol* 2011;  
1537 106:915–922.
- 1538 116. Johannesson E, Ringstrom G, Abrahamsson H, et al.  
1539 Intervention to increase physical activity in irritable bowel  
1540 syndrome shows long-term positive effects. *World J*  
1541 *Gastroenterol* 2015;21:600–608.
- 1542 117. Lacy BE, Pimentel M, Brenner DM, et al. Aa clinical  
1543 guideline: management of irritable bowel syndrome. *Am*  
1544 *J Gastroenterol* 2021;116:17–44.
- 1545 118. Bianco A, Russo F, Franco I, et al. Enhanced physical  
1546 capacity and gastrointestinal symptom improvement in  
1547 southern italian ibs patients following three months of  
1548 moderate aerobic exercise. *J Clin Med* 2023;12.
- 1549 119. Chimienti G, Russo F, Bianco A, et al. Effect of a 12-  
1550 week walking program monitored by global physical  
1551 capacity score (gps) on circulating cell-free mtDNA and  
1552 dnase activity in patients with irritable bowel syndrome.  
1553 *Int J Mol Sci* 2024;25.
- 1554 120. Mazumder S, Bindu S, De R, et al. Emerging role of  
1555 mitochondrial damp, aberrant mitochondrial dynamics  
1556 and anomalous mitophagy in gut mucosal pathogenesis.  
1557 *Life Sci* 2022;305:120753.
- 1558 121. Nunan D, Cai T, Gardener AD, et al. Physical activity for  
1559 treatment of irritable bowel syndrome. *Cochrane Data-*  
1560 *base of Systematic Reviews* 2022.

122. Li C, Li J, Zhou Q, et al. Effects of physical exercise on the microbiota in irritable bowel syndrome. *Nutrients* 2024;16:2657. 1621
123. Arem H, Moore SC, Patel A, et al. Leisure time physical activity and mortality: a detailed pooled analysis of the dose-response relationship. *JAMA Intern Med* 2015; 175:959–967. 1622
124. McTiernan A, Friedenreich CM, Katzmarzyk PT, et al. Physical activity in cancer prevention and survival: a systematic review. *Med Sci Sports Exerc* 2019; 51:1252–1261. 1623
125. Moore SC, Lee IM, Weiderpass E, et al. Association of leisure-time physical activity with risk of 26 types of cancer in 1.44 million adults. *JAMA Intern Med* 2016; 176:816–825. 1624
126. Wang Q, Zhou W. Roles and molecular mechanisms of physical exercise in cancer prevention and treatment. *J Sport Health Sci* 2021;10:201–210. 1625
127. Matthews CE, Moore SC, Arem H, et al. Amount and intensity of leisure-time physical activity and lower cancer risk. *J Clin Oncol* 2020;38:686–697. 1626
128. Cormie P, Zopf EM, Zhang X, et al. The impact of exercise on cancer mortality, recurrence, and treatment-related adverse effects. *Epidemiol Rev* 2017;39:71–92. 1627
129. Robsahm TE, Aagnes B, Hjartåker A, et al. Body mass index, physical activity, and colorectal cancer by anatomical subsites: a systematic review and meta-analysis of cohort studies. *Eur J Cancer Prevent* 2013; 22:492–505. 1628
130. Ruiz-Casado A, Martín-Ruiz A, Pérez LM, et al. Exercise and the hallmarks of cancer. *Trends Cancer* 2017; 3:423–441. 1629
131. Smit KC, Derksen JWG, Beets GLO, et al. Physical activity is associated with improved overall survival among patients with metastatic colorectal cancer. *Cancers (Basel)* 2022;14. 1630
132. McTiernan A, Yasui Y, Sorensen B, et al. Effect of a 12-month exercise intervention on patterns of cellular proliferation in colonic crypts: a randomized controlled trial. *Cancer Epidemiol Biomarkers Prevent* 2006; 15:1588–1597. 1631
133. Conti L, Del Cornò M, Gessani S. Revisiting the impact of lifestyle on colorectal cancer risk in a gender perspective. *Crit Rev Oncol/Hematol* 2020;145:102834. 1632
134. Chao A, Connell CJ, Jacobs EJ, et al. Amount, type, and timing of recreational physical activity in relation to colon and rectal cancer in older adults: the cancer prevention study ii nutrition cohort. *Cancer Epidemiol Biomarkers Prev* 2004;13:2187–2195. 1633
135. Thune I, Furberg AS. Physical activity and cancer risk: dose-response and cancer, all sites and site-specific. *Med Sci Sports Exerc* 2001;33:S530–S550; discussion S609–S610. 1634
136. Sanchez NF, Stierman B, Saab S, et al. Physical activity reduces risk for colon polyps in a multiethnic colorectal cancer screening population. *BMC Res Notes* 2012; 5:312. 1635
137. Psaltopoulou T, Ntanasias-Stathopoulos I, Tzanninis IG, et al. Physical activity and gastric cancer risk: a systematic review and meta-analysis. *Clin J Sport Med* 2016;26:445–464. 1636
138. Behrens G, Jochem C, Keimling M, et al. The association between physical activity and gastroesophageal cancer: systematic review and meta-analysis. *Eur J Epidemiol* 2014;29:151–170. 1637
139. Fang P, Zhou J, Xiao X, et al. The prognostic value of sarcopenia in oesophageal cancer: a systematic review and meta-analysis. *J Cachexia Sarcopenia Muscle* 2023; 14:3–16. 1638
140. Belkaid Y, Hand TW. Role of the microbiota in immunity and inflammation. *Cell* 2014;157:121–141. 1639
141. Ansaldo E, Farley TK, Belkaid Y. Control of immunity by the microbiota. *Ann Rev Immunol* 2021;39:449–479. 1640
142. Rosa-Neto JC, Lira FS, Little JP, et al. Immunometabolism-fit: how exercise and training can modify T cell and macrophage metabolism in health and disease. *Exerc Immunol Rev* 2022;28. 1641
143. Nieman DC, Pence BD. Exercise immunology: future directions. *J Sport Health Sci* 2020;9:432–445. 1642
144. MacNeil B, Hoffman-Goetz L. Effect of exercise on natural cytotoxicity and pulmonary tumor metastases in mice. *Med Sci Sports Exerc* 1993;25:922–928. 1643
145. Deng N, Reyes-Urbe L, Fahrman JF, et al. Exercise training reduces the inflammatory response and promotes intestinal mucosa-associated immunity in lynch syndrome. *Clin Cancer Res* 2023;29:4361–4372. 1644
146. Neish AS. Mucosal immunity and the microbiome. *Ann Am Thor Soc* 2014;11:S28–S32. 1645
147. Sun X, Zhu M-J. Amp-activated protein kinase: a therapeutic target in intestinal diseases. *Open Biol* 2017;7: 170104. 1646
148. Thompson HJ, Jiang W, Zhu Z. Candidate mechanisms accounting for effects of physical activity on breast carcinogenesis. *IUBMB Life* 2009;61:895–901. 1647
149. Hojman P, Gehl J, Christensen JF, et al. Molecular mechanisms linking exercise to cancer prevention and treatment. *Cell Metab* 2018;27:10–21. 1648
150. Wan R, Chen Y, Feng X, et al. Exercise potentially prevents colorectal cancer liver metastases by suppressing tumor epithelial cell stemness via rps4x downregulation. *Heliyon* 2024;10:e26604. 1649
151. Wang T, Cai G, Qiu Y, et al. Structural segregation of gut microbiota between colorectal cancer patients and healthy volunteers. *ISME J* 2012;6:320–329. 1650
152. Warbeck C, Dowd AJ, Kronlund L, et al. Feasibility and effects on the gut microbiota of a 12-week high-intensity interval training plus lifestyle education intervention on inactive adults with celiac disease. *Appl Physiol Nutr Metab* 2021;46:325–336. 1651
153. Craven J, Cox AJ, Bellinger P, et al. The influence of exercise training volume alterations on the gut microbiome in highly-trained middle-distance runners. *Eur J Sport Sci* 2022;22:1222–1230. 1652
154. Aoi W, Inoue R, Mizushima K, et al. Exercise-acclimated microbiota improves skeletal muscle metabolism via circulating bile acid deconjugation. *Iscience* 2023;26. 1653
155. Lai Z-L, Tseng C-H, Ho HJ, et al. Fecal microbiota transplantation confers beneficial metabolic effects of 1654



- 1681 diet and exercise on diet-induced obese mice. *Scientif*  
1682 *Rep* 2018;8:15625.
- 1683 156. Cammarota G, Ianiro G, Tilg H, et al. European  
1684 consensus conference on faecal microbiota trans-  
1685 plantation in clinical practice. *Gut* 2017;66:569–580.
- 1686 157. Gilbert JA, Quinn RA, Debelius J, et al. Microbiome-wide  
1687 association studies link dynamic microbial consortia to  
1688 disease. *Nature* 2016;535:94–103.
- 1689 158. Clooney AG, Eckenberger J, Laserna-Mendieta E, et al.  
1690 Ranking microbiome variance in inflammatory bowel  
1691 disease: a large longitudinal intercontinental study. *Gut*  
1692 2021;70:499–510.
- 1693 159. Ghosh TS, Shanahan F, O’Toole PW. The gut micro-  
1694 biome as a modulator of healthy ageing. *Nat Rev Gas-  
1695 troenterol Hepatol* 2022;19:565–584.
- 1696 160. Claesson MJ, Jeffery IB, Conde S, et al. Gut microbiota  
1697 composition correlates with diet and health in the elderly.  
1698 *Nature* 2012;488:178–184.
- 1699 161. Sallis JF. Age-related decline in physical activity: a  
1700 synthesis of human and animal studies. *Med Sci Sports  
1701 Exerc* 2000;32:1598–1600.
- 1702 162. Grosicki GJ, Fielding RA, Lustgarten MS. Gut microbiota  
1703 contribute to age-related changes in skeletal muscle  
1704 size, composition, and function: biological basis for a  
1705 gut-muscle axis. *Calcif Tissue Int* 2018;102:433–442.
- 1706 163. Ticinesi A, Nouvenne A, Cerundolo N, et al. Gut micro-  
1707 biota, muscle mass and function in aging: a focus on  
1708 physical frailty and sarcopenia. *Nutrients* 2019;11:1633.
- 1709 164. Allen J, Mailing L, Cohrs J, et al. Exercise training-  
1710 induced modification of the gut microbiota persists af-  
1711 ter microbiota colonization and attenuates the response  
1712 to chemically-induced colitis in gnotobiotic mice. *Gut  
1713 Microbes* 2018;9:115–130.

---

Received September 12, 2024. Accepted January 25, 2025.

#### Correspondence

Address correspondence to: John A. Hawley, PhD, Australian Catholic University, Mary MacKillop Institute for Health Research, L 5 215 Spring St, Melbourne, VIC 3000, Australia. e-mail: [John.hawley@acu.edu.au](mailto:John.hawley@acu.edu.au).

#### Conflicts of interest

The authors disclose the following: Samuel C. Forster is a consultant to BiomeBank Australia and has acted as an advisor to Microbiotica. Edward M. Giles is an advisor to AbbVie and Janssen; and has received speaker fees from Takeda, Janssen, Nutricia, Aspen Nutritionals, AbbVie, Evolution Health, and H&H Group. The remaining author discloses no conflicts

#### Funding

No direct funding was received for this work.